Geriatric assessment in Acute Myeloid Leukemia (AML)
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535500. Online ahead of print.ABSTRACTBackground Acute myeloid leukemia (AML) is a heterogenous disease that affects mostly older adults with varying baseline health and functional status. Treatment options have expanded for older adults ranging from less intensive chronic therapies to intensive induction strategies with curative intent. Despite this, outcomes remain poor with advancing age due to underlying disease biology and variability in treatment tolerance. Reliance on chronologic age alone, however, increases risks of both over- and under-treatment. Strategies to better ch...
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Justin D Woods Heidi D Klepin Source Type: research
Test then erase? Current status and future opportunities for Measurable Residual Disease testing in Acute Myeloid Leukemia
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535463. Online ahead of print.ABSTRACTBACKGROUND: Measurable residual disease (MRD) test positivity during and after treatment in patients with acute myeloid leukemia (AML) has been associated with higher rates of relapse and worse overall survival. Current approaches for MRD testing are not standardized leading to inconsistent results and poor prognostication of disease. Pertinent studies evaluating AML MRD testing at specific times points, with various therapeutics and testing methods are presented.SUMMARY: AML is a set of diseases with different molecular and cytogenetic chara...
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Amanda L Blackmon Christopher S Hourigan Source Type: research
Untangling Complexities of Acute Myeloid Leukemia Review Series
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535574. Online ahead of print.NO ABSTRACTPMID:38035554 | DOI:10.1159/000535574 (Source: Acta Haematologica)
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Shai Shimony Richard M Stone Source Type: research
Geriatric assessment in Acute Myeloid Leukemia (AML)
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535500. Online ahead of print.ABSTRACTBackground Acute myeloid leukemia (AML) is a heterogenous disease that affects mostly older adults with varying baseline health and functional status. Treatment options have expanded for older adults ranging from less intensive chronic therapies to intensive induction strategies with curative intent. Despite this, outcomes remain poor with advancing age due to underlying disease biology and variability in treatment tolerance. Reliance on chronologic age alone, however, increases risks of both over- and under-treatment. Strategies to better ch...
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Justin D Woods Heidi D Klepin Source Type: research
Test then erase? Current status and future opportunities for Measurable Residual Disease testing in Acute Myeloid Leukemia
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535463. Online ahead of print.ABSTRACTBACKGROUND: Measurable residual disease (MRD) test positivity during and after treatment in patients with acute myeloid leukemia (AML) has been associated with higher rates of relapse and worse overall survival. Current approaches for MRD testing are not standardized leading to inconsistent results and poor prognostication of disease. Pertinent studies evaluating AML MRD testing at specific times points, with various therapeutics and testing methods are presented.SUMMARY: AML is a set of diseases with different molecular and cytogenetic chara...
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Amanda L Blackmon Christopher S Hourigan Source Type: research
Untangling Complexities of Acute Myeloid Leukemia Review Series
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535574. Online ahead of print.NO ABSTRACTPMID:38035554 | DOI:10.1159/000535574 (Source: Acta Haematologica)
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Shai Shimony Richard M Stone Source Type: research
Geriatric assessment in Acute Myeloid Leukemia (AML)
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535500. Online ahead of print.ABSTRACTBackground Acute myeloid leukemia (AML) is a heterogenous disease that affects mostly older adults with varying baseline health and functional status. Treatment options have expanded for older adults ranging from less intensive chronic therapies to intensive induction strategies with curative intent. Despite this, outcomes remain poor with advancing age due to underlying disease biology and variability in treatment tolerance. Reliance on chronologic age alone, however, increases risks of both over- and under-treatment. Strategies to better ch...
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Justin D Woods Heidi D Klepin Source Type: research
Test then erase? Current status and future opportunities for Measurable Residual Disease testing in Acute Myeloid Leukemia
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535463. Online ahead of print.ABSTRACTBACKGROUND: Measurable residual disease (MRD) test positivity during and after treatment in patients with acute myeloid leukemia (AML) has been associated with higher rates of relapse and worse overall survival. Current approaches for MRD testing are not standardized leading to inconsistent results and poor prognostication of disease. Pertinent studies evaluating AML MRD testing at specific times points, with various therapeutics and testing methods are presented.SUMMARY: AML is a set of diseases with different molecular and cytogenetic chara...
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Amanda L Blackmon Christopher S Hourigan Source Type: research
Untangling Complexities of Acute Myeloid Leukemia Review Series
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535574. Online ahead of print.NO ABSTRACTPMID:38035554 | DOI:10.1159/000535574 (Source: Acta Haematologica)
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Shai Shimony Richard M Stone Source Type: research
Geriatric assessment in Acute Myeloid Leukemia (AML)
Acta Haematol. 2023 Nov 30. doi: 10.1159/000535500. Online ahead of print.ABSTRACTBackground Acute myeloid leukemia (AML) is a heterogenous disease that affects mostly older adults with varying baseline health and functional status. Treatment options have expanded for older adults ranging from less intensive chronic therapies to intensive induction strategies with curative intent. Despite this, outcomes remain poor with advancing age due to underlying disease biology and variability in treatment tolerance. Reliance on chronologic age alone, however, increases risks of both over- and under-treatment. Strategies to better ch...
Source: Acta Haematologica - November 30, 2023 Category: Hematology Authors: Justin D Woods Heidi D Klepin Source Type: research
In Memoriam: Isaac Ben-Bassat (1937-2023) A Lifelong Legacy in Hematology
Acta Haematol. 2023 Nov 24:1-2. doi: 10.1159/000535013. Online ahead of print.NO ABSTRACTPMID:38008062 | DOI:10.1159/000535013 (Source: Acta Haematologica)
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Pia Raanani Source Type: research
Long-term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma: A Retrospective Study
CONCLUSIONS: Optimized treatment based on anatomical location, pulmonary function, and disease stage can improve long-term survival in patients with pulmonary MALT lymphoma.PMID:38008071 | DOI:10.1159/000535228 (Source: Acta Haematologica)
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Gi-June Min Chin Kook Rhee Tong Yoon Kim Young-Woo Jeon Joo Hyun O Byung-Ock Choi Gyeongsin Park Seok-Goo Cho Source Type: research
Optimal post-remission consolidation therapy in patients with AML
Acta Haematol. 2023 Nov 26. doi: 10.1159/000535457. Online ahead of print.ABSTRACTBACKGROUND: Despite recent advances, 40-85% of patients with acute myeloid leukemia (AML) achieve complete remission after intensive chemotherapy. However, without optimal treatment after remission, the risk of relapse remains high.SUMMARY: A variable number of consolidation cycles consisting of intermediate doses of cytarabine are the most commonly used regimens in low-intermediate risk AML, while patients at higher risk of relapse should consolidate response by proceeding to HSCT. Different post-consolidation (maintenance therapies) have de...
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Carlos Jimenez-Chillon Richard Dillon Nigel Russell Source Type: research
In Memoriam: Isaac Ben-Bassat (1937-2023) A Lifelong Legacy in Hematology
Acta Haematol. 2023 Nov 24:1-2. doi: 10.1159/000535013. Online ahead of print.NO ABSTRACTPMID:38008062 | DOI:10.1159/000535013 (Source: Acta Haematologica)
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Pia Raanani Source Type: research
Long-term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma: A Retrospective Study
CONCLUSIONS: Optimized treatment based on anatomical location, pulmonary function, and disease stage can improve long-term survival in patients with pulmonary MALT lymphoma.PMID:38008071 | DOI:10.1159/000535228 (Source: Acta Haematologica)
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Gi-June Min Chin Kook Rhee Tong Yoon Kim Young-Woo Jeon Joo Hyun O Byung-Ock Choi Gyeongsin Park Seok-Goo Cho Source Type: research
